Abstract
An increasing volume of pre-clinical and clinical-translational research is attempting to identify novel biomarkers for improved diagnosis and risk-stratification of chemotherapy-induced cardiotoxicity. Most published animal models have employed weekly intraperitoneal injections of doxorubicin to reach a desired cumulative dose. This approach can be associated with severe systemic toxicity which limits the animal model usefulness, particularly for advanced imaging. In the current study, slow-release subcutaneous doxorubicin pellets demonstrated histopathologic evidence of cardiotoxicity at doses similar to standard human dose-equivalents without limiting animal survival or ability to participate in advanced imaging studies. This approach may provide a more robust cardiotoxicity animal model.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 482-484 |
| Number of pages | 3 |
| Journal | Cardiovascular Toxicology |
| Volume | 19 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2019 |
Funding
This work was supported by Northwestern University’s Center for Advanced Microscopy and a Cancer Center Support Grant (NCI CA060553). Histology services were provided by the Northwestern University Mouse Histology and Phenotyping Laboratory which is supported by NCI P30-CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center. The authors also acknowledge Quanhong Grace Ma, Research Lab Manager, Northwestern University Department of Radiology for her contributions to this project.
Keywords
- Animal model
- Cardio-oncology
- Cardiotoxicity
- Chemotherapy
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Molecular Biology
- Toxicology
